313 related articles for article (PubMed ID: 25446100)
1. QCM-4, a 5-HT₃ receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice.
Kurhe Y; Mahesh R; Devadoss T
Biochem Biophys Res Commun; 2015 Jan; 456(1):74-9. PubMed ID: 25446100
[TBL] [Abstract][Full Text] [Related]
2. Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.
Kurhe Y; Mahesh R
Pharmacol Biochem Behav; 2015 Sep; 136():107-16. PubMed ID: 26188166
[TBL] [Abstract][Full Text] [Related]
3. QCM-4, a serotonergic type 3 receptor modulator attenuates depression co-morbid with obesity in mice: an approach based on behavioral and biochemical investigations.
Kurhe Y; Mahesh R; Gupta D; Devadoss T
Eur J Pharmacol; 2014 Oct; 740():611-8. PubMed ID: 24973694
[TBL] [Abstract][Full Text] [Related]
4. QCM-4 a novel 5-HT3 antagonist attenuates the behavioral and biochemical alterations on chronic unpredictable mild stress model of depression in Swiss albino mice.
Kurhe Y; Radhakrishnan M; Gupta D; Devadoss T
J Pharm Pharmacol; 2014 Jan; 66(1):122-32. PubMed ID: 24180368
[TBL] [Abstract][Full Text] [Related]
5. 5HT3 receptor antagonist (ondansetron) reverses depressive behavior evoked by chronic unpredictable stress in mice: modulation of hypothalamic-pituitary-adrenocortical and brain serotonergic system.
Gupta D; Radhakrishnan M; Kurhe Y
Pharmacol Biochem Behav; 2014 Sep; 124():129-36. PubMed ID: 24909071
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression.
Gupta D; Radhakrishnan M; Kurhe Y; Thangaraj D; Prabhakar V; Kanade P
Acta Pharmacol Sin; 2014 Dec; 35(12):1493-503. PubMed ID: 25418380
[TBL] [Abstract][Full Text] [Related]
7. Novel 5-HT
Kurhe Y; Mahesh R; Devadoss T
Psychopharmacology (Berl); 2017 Apr; 234(7):1165-1179. PubMed ID: 28238069
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of a novel 5-HT3 receptor antagonist, N-n-butyl-3-methoxy quinoxaline-2-carboxamide (6o) against chronic unpredictable mild stress-induced behavioral changes and biochemical alterations.
Bhatt S; Mahesh R; Jindal A; Devadoss T
Pharmacol Biochem Behav; 2014 Jul; 122():234-9. PubMed ID: 24769308
[TBL] [Abstract][Full Text] [Related]
9. Effect of (4a) a novel 5-HT3 receptor antagonist on chronic unpredictable mild stress induced depressive-like behavior in mice: an approach using behavioral tests battery.
Kurhe Y; Mahesh R; Gupta D; Thangaraj D
J Basic Clin Physiol Pharmacol; 2015 Jan; 26(1):25-33. PubMed ID: 24706431
[TBL] [Abstract][Full Text] [Related]
10. Effect of a novel 5-HT3 receptor antagonist 4i, in corticosterone-induced depression-like behavior and oxidative stress in mice.
Gupta D; Radhakrishnan M; Kurhe Y
Steroids; 2015 Apr; 96():95-102. PubMed ID: 25668613
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models.
Gupta D; Radhakrishnan M; Thangaraj D; Kurhe Y
Eur J Pharmacol; 2014 Jul; 735():59-67. PubMed ID: 24747753
[TBL] [Abstract][Full Text] [Related]
12. Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system.
Gupta D; Radhakrishnan M; Kurhe Y
Eur J Pharmacol; 2014 Dec; 744():59-66. PubMed ID: 25284215
[TBL] [Abstract][Full Text] [Related]
13. Neuropharmacological effect of novel 5-HT3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) on chronic unpredictable mild stress-induced molecular and cellular response: Behavioural and biochemical evidences.
Bhatt S; Mahesh R; Jindal A; Devadoss T
Pharmacol Rep; 2014 Oct; 66(5):804-10. PubMed ID: 25149984
[TBL] [Abstract][Full Text] [Related]
14. Ondansetron ameliorates depression associated with obesity in high-fat diet fed experimental mice: An investigation-based on the behavioral, biochemical, and molecular approach.
Kurhe Y; Mahesh R
Indian J Pharmacol; 2017; 49(4):290-296. PubMed ID: 29326489
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms linking depression co-morbid with obesity: An approach for serotonergic type 3 receptor antagonist as novel therapeutic intervention.
Kurhe Y; Mahesh R
Asian J Psychiatr; 2015 Oct; 17():3-9. PubMed ID: 26243683
[TBL] [Abstract][Full Text] [Related]
16. Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests.
Kurhe Y; Radhakrishnan M; Gupta D
Metab Brain Dis; 2014 Sep; 29(3):701-10. PubMed ID: 24964970
[TBL] [Abstract][Full Text] [Related]
17. Interactions of atenolol with alprazolam/escitalopram on anxiety, depression and oxidative stress.
Shahzad N; Ahmad J; Khan W; Al-Ghamdi SS; Ain MR; Ibrahim IA; Akhtar M; Khanam R
Pharmacol Biochem Behav; 2014 Feb; 117():79-84. PubMed ID: 24361783
[TBL] [Abstract][Full Text] [Related]
18. Agarwood Essential Oil Ameliorates Restrain Stress-Induced Anxiety and Depression by Inhibiting HPA Axis Hyperactivity.
Wang S; Wang C; Yu Z; Wu C; Peng D; Liu X; Liu Y; Yang Y; Guo P; Wei J
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400578
[TBL] [Abstract][Full Text] [Related]
19. Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice.
Thoeringer CK; Erhardt A; Sillaber I; Mueller MB; Ohl F; Holsboer F; Keck ME
J Psychopharmacol; 2010 May; 24(5):733-43. PubMed ID: 19346277
[TBL] [Abstract][Full Text] [Related]
20. Neuropharmacological and neurochemical evaluation of N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n): a novel serotonergic 5-HT3 receptor antagonist for co-morbid antidepressant- and anxiolytic-like potential using traumatic brain injury model in rats.
Bhatt S; Mahesh R; Jindal A; Devadoss T
J Basic Clin Physiol Pharmacol; 2017 Mar; 28(2):93-100. PubMed ID: 27662644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
